press releases
Download our latest press release
June 2026
The successful ₹100+ Crore Series B funding and widespread national media recognition reinforce Immuneel’s commitment to making advanced cell and gene therapies more accessible to patient…
Read more
June 2026
CEO & Board Director Amit Mookim, in an exclusive interview with CNBC Awaaz, shares Immuneel’s vision of transforming cancer care through advanced cell and gene therapies. From the su…
Read more
February 2026
Immuneel Therapeutics and Manas AI to Explore the Potential of AI-Driven Frameworks for Next-Generation Biologics, ADCs, and in-vivo gene-based therapies
Read more
January 2026
Immuneel Therapeutics Partners with Impact Guru and CarePal Money to Improve Financial Access to CAR T-Cell Therapy in India
Read more
August 2025
India’s First CAR T-Cell Therapy Shows Durable Results: Two-Year Remission Achieved in Blood Cancer Patients
Read more
January 2025
Immuneel Therapeutics Launches Qartemi® – India’s First Global CAR T-cell Therapy for Non-Hodgkin’s Lymphoma
Read more
13th December, 2022
Immuneel Therapeutics Presents Early data from India for Varnimcabtagene autoleucel (IMAGINE, Phase 2) at ASH Annual Meeting 2022, USA.
Read more
21st June, 2022
Biotech start-up Immuneel Therapeutics announces India’s first Phase II patient trials for CAR-T cancer therapies alongside a USD 15 million Series A financing
Read more
18th January, 2021
Immuneel Announces the Inauguration of India’s first Integrated Cell Therapy Development and Manufacturing Facility
Read more
13th October, 2020
Immuneel Therapeutics, Hospital Clínic de Barcelona & Institut d’Investigacions Biomèdiques August Pi i Sunyer Announce a Strategic collaboration & a License Agreement.
Read more